Your browser doesn't support javascript.
loading
Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens.
Yan, Dan; Weisshaar, Marco; Lamb, Kristen; Chung, Hokyung K; Lin, Michael Z; Plemper, Richard K.
Afiliação
  • Yan D; Institute for Biomedical Sciences, Georgia State University , Atlanta, Georgia 30303-3222, United States.
  • Weisshaar M; Institute for Biomedical Sciences, Georgia State University , Atlanta, Georgia 30303-3222, United States.
  • Lamb K; Institute for Biomedical Sciences, Georgia State University , Atlanta, Georgia 30303-3222, United States.
  • Chung HK; Department of Biology, Stanford University , Stanford, California 94305-5020, United States.
  • Lin MZ; Department of Bioengineering, Stanford University , Stanford, California 94305, United States.
  • Plemper RK; Department of Pediatrics, Stanford University , Stanford, California 94305, United States.
Biochemistry ; 54(36): 5589-604, 2015 Sep 15.
Article em En | MEDLINE | ID: mdl-26307636
ABSTRACT
Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus da Influenza A / Vírus Sinciciais Respiratórios Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Vírus da Influenza A / Vírus Sinciciais Respiratórios Idioma: En Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Estados Unidos